Compared with conventional imaging alone, PSMA-PET imaging was estimated to increase the number of life-years by 988 (95% UI, 821-1146 life-years) or 824 QALYs (95% UI, 698-885 QALYs) and lead to 75 (95% UI, 66-81) fewer deaths from prostate cancer per 1000 patients with BCR (Table 3). The gene discussed is FOLH1; the disease is prostate cancer.